PUBLISHER: IMARC | PRODUCT CODE: 1540871
PUBLISHER: IMARC | PRODUCT CODE: 1540871
The global vascular grafts market size reached US$ 1.9 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 3.2 Billion by 2032, exhibiting a growth rate (CAGR) of 5.7% during 2024-2032. The increasing number of fatal road accidents and trauma cases, rising inclination towards medical tourism, and the growing number of surgical procedures, especially among the geriatric population, are some of the major factors propelling the market.
Vascular grafts are medical devices used to replace, bypass, or restore functionality to damaged or diseased blood vessels in the human body. They serve as artificial conduits that facilitate blood flow and ensure that vital organs and tissues receive adequate blood supply. They can be made from various materials, including synthetic polymers like dacron and teflon or biological materials like vein segments harvested from the patient or a donor. They are commonly used in surgical procedures, such as coronary artery bypass grafting (CABG), peripheral artery bypass, and hemodialysis access.
The increasing number of fatal road accidents and the expanding number of trauma cases are driving the demand for vascular grafts around the world. Moreover, the rising inclination towards medical tourism, wherein people are traveling to countries with advanced healthcare systems for specialized treatments, including vascular graft surgeries, is favoring the growth of the market. In addition, the growing number of surgical procedures and the rising global geriatric population, which is more susceptible to medical disorders, are influencing the market positively. Apart from this, the increasing focus on preventive healthcare, which leads to early diagnosis and treatment of vascular conditions, is catalyzing the need for vascular grafts as a preemptive measure. Furthermore, the growing number of ambulatory surgical centers, which offer quicker and more convenient surgical procedures, are creating a positive outlook for the market.
Increase in prevalence of lifestyle diseases
One of the primary factors that are driving the demand for vascular grafts is the surging prevalence of lifestyle-related diseases like obesity and diabetes. These conditions significantly elevate the risk of developing vascular problems that may necessitate graft surgeries. As lifestyle diseases continue to surge, the requirement for vascular grafts to manage associated vascular complications is likely to grow substantially.
Rise in public awareness and education
Increasing public awareness about vascular diseases and the available treatment options is also catalyzing thee demand for vascular grafts. Public health campaigns, educational programs, and digital platforms are educating people about the risks of vascular conditions and the importance of early diagnosis and treatment. This heightened awareness is leading to more people seeking medical advice and, consequently, increasing the number of vascular graft surgeries being performed.
Growing regulatory approvals and reimbursement policies
Favorable regulatory approvals and reimbursement policies play a crucial role in driving the market for vascular grafts. Regulatory bodies of numerous countries have stringent but clear pathways for the approval of new medical devices, including vascular grafts. Once approved, these products are more readily adopted by medical facilities. Additionally, comprehensive reimbursement policies make it financially feasible for patients to opt for these advanced treatments, further elevating the demand for vascular grafts in the market.
IMARC Group provides an analysis of the key trends in each segment of the global vascular grafts market report, along with forecasts at the global, regional, and country levels for 2024-2032. Our report has categorized the market based on product, raw material, application, and end user.
Endovascular Stent Grafts
Hemodialysis Access Grafts
Coronary Artery By-Pass Grafts
Vascular Grafts for Aorta Disease
Peripheral Vascular Grafts
Endovascular stent grafts dominate the market
The report has provided a detailed breakup and analysis of the market based on the product. This includes endovascular stent grafts, hemodialysis access grafts, coronary artery by-pass grafts, vascular grafts for aorta disease, and peripheral vascular grafts. According to the report, endovascular stent grafts represented the largest segment. Endovascular stent grafts are a specialized type of vascular graft used primarily for treating conditions like abdominal aortic aneurysms and thoracic aortic aneurysms. They can be placed using minimally invasive (MI) surgical techniques. A catheter is used to deliver the stent graft to the affected area through a small incision, usually in the groin. The MI nature of the procedure generally leads to shorter recovery times and less postoperative pain.
Hemodialysis access grafts serve a different purpose but are equally important in the field of medicine. They are used to provide reliable and durable vascular access for patients who require long-term hemodialysis, a treatment for kidney failure. Typically made of synthetic materials like PTFE (polytetrafluoroethylene), these grafts are surgically implanted to connect an artery to a vein, usually in the arm. Hemodialysis access grafts offer the advantage of immediate use, as opposed to AV fistulas that often require weeks to mature before they can be used for dialysis.
Polytetrafluoroethylene (PTFE)
Polyester
Polyurethane
Biosynthetic
Polytetrafluoroethylene (PTFE) holds the largest share in the market
A detailed breakup and analysis of the market based on the raw material has also been provided in the report. This includes polytetrafluoroethylene (PTFE), polyester, polyurethane, and biosynthetic. According to the report, polytetrafluoroethylene (PTFE) accounted for the largest market share. Polytetrafluoroethylene (PTFE) is a type of synthetic fluoropolymer that is frequently used as a raw material in the manufacture of vascular grafts. It is known for its chemical inertness, biocompatibility, and low friction coefficient, which makes it a suitable material for medical applications. It is particularly popular for use in hemodialysis access grafts. PTFE grafts are often ready for immediate use after implantation, unlike some other types of grafts that require time to mature.
Polyester is another widely used synthetic material in the construction of vascular grafts, particularly in applications like aortic and peripheral vascular bypass surgeries. Often sold under the brand name Dacron, polyester vascular grafts have been used for several decades and have a well-established safety and efficacy profile. Polyester is known for its excellent mechanical properties, including tensile strength and durability, which makes it a preferred choice for long-term implantation. It also possesses good biocompatibility and allows for tissue ingrowth, which helps in anchoring the graft securely in place over time.
Cardiac Aneurysm
Kidney Failure
Vascular Occlusion
Coronary Artery Disease
Cardiac aneurysm dominates the market
The report has provided a detailed breakup and analysis of the market based on the application. This includes cardiac aneurysm, kidney failure, vascular occlusion, and coronary artery disease. According to the report, cardiac aneurysm represented the largest segment. Vascular grafts have a critical role in the treatment of cardiac aneurysms, which are localized, abnormal bulges that occur in the wall of heart chambers or arteries. The use of vascular grafts in this context aims to bypass or replace the weakened section of the blood vessel or heart wall, thus preventing rupture and subsequent life-threatening events. In surgeries, such as coronary artery bypass grafting (CABG), graft materials like polyester or PTFE can be used to reroute blood flow around blocked or compromised arteries, thus restoring adequate blood supply to heart muscles.
In the context of kidney failure, vascular grafts are commonly used to create a functional access point for hemodialysis. When a kidney fails of a patient to adequately filter blood, hemodialysis becomes necessary to remove waste products. Reliable vascular access is crucial for this process. Hemodialysis access grafts, often made from PTFE, are used to surgically connect an artery to a vein, usually in the arm. This connection, known as an arteriovenous (AV) graft, provides a high-flow circuit that facilitates efficient blood removal and return during dialysis sessions. These grafts are particularly useful for patients who cannot use an arteriovenous fistula, either due to poor vein quality or other medical considerations.
Hospitals
Ambulatory Surgical Centers (ASCs)
Hospitals hold the largest share in the market
A detailed breakup and analysis of the market based on the end user has also been provided in the report. This includes hospitals and ambulatory surgical centers (ASCs). According to the report, hospitals accounted for the largest market share. Hospitals are one of the primary end users of vascular grafts. In a hospital setting, vascular grafts are utilized in a variety of surgical procedures including coronary artery bypass grafting (CABG), treatment of aneurysms, and peripheral artery disease interventions. Hospitals often have the comprehensive medical infrastructure, including specialized surgical units, advanced diagnostic equipment, and postoperative care facilities, that allow for the successful implantation and maintenance of these grafts. Given the complexity of many vascular surgeries and the need for specialized medical personnel, such as cardiovascular surgeons and interventional radiologists, hospitals are well-suited to be major end users of vascular grafts.
Ambulatory surgical centers (ASCs) also serve as significant end users of vascular grafts, although their scope may be more limited as compared to hospitals. ASCs are healthcare facilities wherein surgeries that do not require an overnight hospital stay are performed. Due to advancements in minimally invasive surgical (MIS) techniques, certain procedures involving vascular grafts, such as some types of endovascular stent placements, can now be conducted in these settings. ASCs offer the advantage of quicker patient turnover, lower cost, and a more streamlined patient experience.
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
North America exhibits a clear dominance, accounting for the largest vascular grafts market share
The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share.
The surging prevalence of diabetes among the masses represents one of the primary factors bolstering the market growth in the North American region. Moreover, the rising adoption of cutting-edge diagnostic technologies like AI and advanced imaging is contributing to the market growth in the region. Besides this, the growing preference for MI surgeries is influencing the market positively.
The leading companies are developing bioengineered and drug-eluting grafts that aim to mitigate these drawbacks by incorporating living cells or biological molecules to improve biocompatibility and encourage tissue integration. They are also coated with pharmaceutical agents that are slowly released into the bloodstream, which reduces the risk of clot formation and vessel narrowing post-surgery. Moreover, key players are adopting the use of 3D printing technologies to create custom vascular grafts that match the specific anatomical needs of individual patients and reduce the risk of complications that can arise from ill-fitting grafts. They are also utilizing nanotechnology to offer unique mechanical and biological properties, which include better flexibility and reduced thrombogenicity.
Abbott Laboratories
B. Braun SE (B. Braun Holding GmbH & Co. KG)
Becton, Dickinson and Company
Cook Group Incorporated
Cordis
CryoLife Inc.
Getinge AB
Heat Medical Europe BV
LeMaitre Vascular
Medtronic plc
Terumo Corporation
W. L. Gore & Associates Inc.
In 2021, Terumo Corporation announced about the approval of US Food and Drug Administration (FDA) for the TREO(TM) Abdominal Aortic Stent-Graft System for sale in the United States. It assists in the treatment of patients with abdominal aortic aneurysms (AAA).
In 2023, Abbott Laboratories recently acquired Cardiovascular Systems, Inc., which is a medical device company with an innovative atherectomy system used in treating peripheral and coronary artery disease.
In 2022 , B. Braun SE (B. Braun Holding GmbH & Co. KG) acquired the innovative Clik-FIX catheter securement device portfolio from Starboard Medical, Inc. to expand their product portfolio.